These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32406293)

  • 1. Toripalimab for the treatment of melanoma.
    Tang B; Chi Z; Guo J
    Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab use for the treatment of advanced melanoma.
    Specenier P
    Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
    Li S; Wu X; Yan X; Zhou L; Chi Z; Si L; Cui C; Tang B; Mao L; Lian B; Wang X; Bai X; Dai J; Kong Y; Tang X; Feng H; Yao S; Flaherty KT; Guo J; Sheng X
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.
    Zhang L; Hao B; Geng Z; Geng Q
    Front Immunol; 2021; 12():730666. PubMed ID: 35095833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
    Liu H; Guo L; Zhang J; Zhou Y; Zhou J; Yao J; Wu H; Yao S; Chen B; Chai Y; Qi J; Gao GF; Tan S; Feng H; Yan J
    MAbs; 2019; 11(4):681-690. PubMed ID: 30892132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toripalimab: First Global Approval.
    Keam SJ
    Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
    Tang B; Chi Z; Chen Y; Liu X; Wu D; Chen J; Song X; Wang W; Dong L; Song H; Wu H; Feng H; Yao S; Qin S; Zhang X; Guo J
    Clin Cancer Res; 2020 Aug; 26(16):4250-4259. PubMed ID: 32321714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
    Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
    Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
    Lian B; Li Z; Wu N; Li M; Chen X; Zheng H; Gao M; Wang D; Sheng X; Tian H; Si L; Chi Z; Wang X; Lai Y; Sun T; Zhang Q; Kong Y; Long GV; Guo J; Cui C
    Ann Oncol; 2024 Feb; 35(2):211-220. PubMed ID: 37956739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.
    Tang B; Duan R; Zhang X; Qin S; Wu D; Chen J; Yao H; Chi Z; Guo J; Yan X
    Oncologist; 2024 Jun; 29(6):e822-e827. PubMed ID: 38547052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.